A Large‐Scale Retrospective Study of Serum Des‐Gamma‐Carboxy Prothrombin as a Diagnostic Marker of HCC : Effect of Liver Function on Specificity

作者：Hong Bu, Weijia Luo, Wenli Tao, Chen Dong, Meifang Wang, Ye Xu, Xi Zeng, Boqing Wang, Chang Liu, Yu Qi, Deliang Cao, Hongyu Deng, Yuemin Nan · 发表于：Journal of Clinical Laboratory Analysis · 年份：2025 · DOI：10.1002/jcla.70025 · 被引用次数：3 · 研究领域：Hepatocellular Carcinoma Treatment and Prognosis、Liver Disease Diagnosis and Treatment、Neuroendocrine Tumor Research Advances

BACKGROUND: This retrospective multicenter study is aimed at evaluating the diagnostic accuracy and influence factors of serum des-gamma-carboxy prothrombin (DCP) as a diagnostic biomarker of hepatocellular carcinoma (HCC). METHODS: Clinical data were collected from 4555 subjects with DCP tests, composed of primary liver cancer (PLC), metastatic liver cancer (MLC), chronic hepatitis (CH), liver cirrhosis (LC), benign liver diseases (BLD), biliary tract diseases (BTD), non-liver cancers (NLC), and non-liver benign diseases (NLBD). The clinical data collected included medical history, treatment records, various serum tests, and imaging examination. RESULTS: Serum DCP was measured with Abbott agents in each center. In HCC, serum DCP concentration was at 9086.00 ± 366.10 mAU/mL, higher than that in other diseases (p < 0.05). At 40.00 mAU/mL recommended by instruction, positive rates of serum DCP were at 85.11% in HCC, 30.12% in intrahepatic cholangiocellular carcinoma (ICC), 31.65% in MLC, 13.95% in BLD, 18.14% in CH, 27.87% in LC, 15.75% in BTD, 35.29% in NLC, and 20.00% in NLBD. In this study, the diagnostic specificity of serum DCP in HCC was affected by liver function. In HCC, serum AFP concentrations also increased compared to non-HCC diseases (p < 0.05), but specificity varied with agents from different providers. Serum DCP decreased after the surgical removal of HCC, but remained elusive in systemic treatment. CONCLUSION: Serum DCP may serve as an optimal biomarker for the...